학술논문

Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells
Document Type
article
Source
Cell Stem Cell. 27(4)
Subject
Biomedical and Clinical Sciences
Oncology and Carcinogenesis
Stem Cell Research - Induced Pluripotent Stem Cell
Stem Cell Research - Nonembryonic - Human
Lung
Genetics
Cancer
Lung Cancer
Stem Cell Research - Induced Pluripotent Stem Cell - Human
Stem Cell Research - Nonembryonic - Non-Human
Biotechnology
Stem Cell Research
Rare Diseases
2.1 Biological and endogenous factors
Animals
Humans
Induced Pluripotent Stem Cells
Mice
Organoids
Proteomics
Proto-Oncogene Proteins p21(ras)
KRAS
alveolar
developmental programs
early-stage lung cancer
iPSC
loss of differentiation
organoid
single-cell RNA sequencing
stage IA lung adenocarcinoma
tumor progression
Biological Sciences
Medical and Health Sciences
Developmental Biology
Biological sciences
Biomedical and clinical sciences
Language
Abstract
Mutant KRAS is a common driver in epithelial cancers. Nevertheless, molecular changes occurring early after activation of oncogenic KRAS in epithelial cells remain poorly understood. We compared transcriptional changes at single-cell resolution after KRAS activation in four sample sets. In addition to patient samples and genetically engineered mouse models, we developed organoid systems from primary mouse and human induced pluripotent stem cell-derived lung epithelial cells to model early-stage lung adenocarcinoma. In all four settings, alveolar epithelial progenitor (AT2) cells expressing oncogenic KRAS had reduced expression of mature lineage identity genes. These findings demonstrate the utility of our in vitro organoid approaches for uncovering the early consequences of oncogenic KRAS expression. This resource provides an extensive collection of datasets and describes organoid tools to study the transcriptional and proteomic changes that distinguish normal epithelial progenitor cells from early-stage lung cancer, facilitating the search for targets for KRAS-driven tumors.